Catalyst
Slingshot members are tracking this event:
Amicus Therapeutics (FOLD) expecting data from Phase 3 ESSENCE study testing SD-101 on Epidermylosis Bullosa (EB) disease in third quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FOLD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 13, 2017
Occurred Source:
http://ir.amicusrx.com/releasedetail.cfm?ReleaseID=1040210
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Essence Study, Phase 3 Study, Epidermolysis Bullosa, Sd-101
